Our study showed an exceptionally high prevalence of the blaNDM gene among CRE clinical isolates. Either aztreonam-avibactam or cefiderocol was found to be effective against 98% of CRE isolates highlighting the immediate need of making these two drugs accessible to patients in India.
Sengupta et al. (Thu,) studied this question.